Ontuxizumab
Monoclonal antibody
- none
- 946415-62-9
- none
- 0M2XT000YC
Ontuxizumab[1] is a humanized rabbit monoclonal antibody[2] designed for the treatment of cancer. It binds to endosialin (TEM1 or CD248).[3]
Phase I trials are complete and the drug was granted orphan drug status by the FDA for sarcoma. It is currently in phase II trials for melanoma, colorectal cancer, sarcoma, and lymphoma.[4]
This drug was developed by Morphotek and Ludwig Institute for Cancer Research.[4]
References
- ^ World Health Organization (2013). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 109" (PDF). WHO Drug Information. 27 (2).
- ^ US 20100260769, Sass PM, Kline B, Nicolaides N, Grasso L, Harley S, "Endosialin binding molecules", published 2010-04-08, assigned to Morphotek Inc
- ^ Kiyohara E, Donovan N, Takeshima L, Huang S, Wilmott JS, Scolyer RA, et al. (August 2015). "Endosialin Expression in Metastatic Melanoma Tumor Microenvironment Vasculature: Potential Therapeutic Implications". Cancer Microenvironment. 8 (2): 111–8. doi:10.1007/s12307-015-0168-8. PMC 4542822. PMID 26085332.
- ^ a b "Ontuxizumab". Adis Insight. Springer Nature Switzerland AG.
- v
- t
- e
Monoclonal antibodies for tumors
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e